MediWound Appoints New CEO, Reports Q2 Financials

TL;DR

MediWound has a new CEO, Gili Harir, effective immediately. Q2 financials also released.

AI Summary

On August 15, 2024, MediWound Ltd. announced the appointment of Dr. Gili Harir as its new Chief Executive Officer, effective immediately. Dr. Harir, who previously served as the company's Chief Business Officer, will succeed Dr. Sharon Malka. The company also reported its financial results for the second quarter ended June 30, 2024.

Why It Matters

A leadership change at the CEO level can signal a shift in company strategy or operational focus, potentially impacting future performance and investor sentiment.

Risk Assessment

Risk Level: medium — Leadership changes and financial reporting can introduce uncertainty and volatility for investors.

Key Players & Entities

• MediWound Ltd. (company) — The company filing the report and making announcements.
• Gili Harir (person) — Newly appointed Chief Executive Officer.
• Sharon Malka (person) — Outgoing Chief Executive Officer.
• August 15, 2024 (date) — Date of the press release and CEO appointment.
• June 30, 2024 (date) — End date for the reported second quarter financial results.

FAQ

Filing Documents

• zk2431877.htm (6-K) — 11KB
• exhibit_99-1.htm (EX-99.1) — 15KB
• image00001.jpg (GRAPHIC) — 4KB
• 0001178913-24-002658.txt ( ) — 33KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): EXPLANATORY NOTE On August 15, 2024, MediWound Ltd. (the "Company") issued a press release entitled "MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns". A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") as Exhibit 99.1. The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company), is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023 (Registration Nos. 333-265203 and 333-268297, respectively). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MEDIWOUND LTD. Date: August 15, 2024 By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer 3 EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit Description 99.1 Press release dated August 15, 2024 entitled "MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns". 4

View Full Filing

View this 6-K filing on SEC EDGAR